Forskning ved Københavns Universitet - Københavns Universitet


Sodium-glucose cotransporter (SGLT)-2-inhibitorer til patienter med type 2-diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

Bidragets oversatte titelSodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
TidsskriftUgeskrift for Laeger
Udgave nummer26
Sider (fra-til)2461-64
StatusUdgivet - 26 dec. 2016

ID: 181027142